CTLA4 and metastatic melanoma: Although the latest ASCO recommendations allow the treatment of patients with metastatic melanoma with anti-PD-1 monotherapy or in combination with anti-CTLA-4 or anti-Lag3 (Seth et al, 2023), the current trend is to treat these patients with the combination therapy with anti-CTLA-4 due to its remarkable long-term outcomes.